All News

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

After my diagnosis, I found a healing balm in an unexpected place. I never knew art would become so vital to my healing.

Dr. Olalekan O. Oluwole, discusses treating patients from underserved communities with CAR T-cell therapy, as well as highlighted the therapy's evolution.

Kasey Bowden highlights the importance of recognizing financial toxicity and shares advice with those who feel lost in the healthcare system during cancer.

CURE spoke with an expert to learn what patients need to know about immunotherapy-induced diabetes.

In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic approaches across a range of disease types.

LiveLung invites the Wilmington community to its monthly educational meeting.

The August LiveLung Virtual meeting will feature Nitin Ohri, MD, MS, Board Certified Radiation Oncologist and Professor of Radiation Oncology at Montefiore Einstein.

LiveLung invites the Triad lung cancer community to its monthly educational meeting.

Robotic and video-assisted thoracic surgery reduces recovery time for those with lung cancer, allowing some to leave the hospital the day after surgery.

BMT-CARE app boosted quality of life, lowered depression and PTSD symptoms, and improved coping mechanisms for caregivers of stem cell transplant patients.

Dr. Michael Wagner covers the basics of epithelioid hemangioendothelioma, a rare vascular cancer, spanning symptoms, diagnosis, treatment options and more.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

The U.S. FDA has granted fast track designation to treatment with CLD-201, an oncolytic virus, for patients with soft tissue sarcoma.

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC.

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.

Dr. Janet Kukreja explains one urinary diversion option available to patients undergoing bladder removal.

A resilience program for young people with advanced cancer helped patients cope early on and led to a better quality of life after 6 to 12 months.

As July concludes, new treatments offer advances across kidney and bladder cancer, with breakthroughs in personalized vaccines and non-surgical therapies.

Writing helped me focus on gratitude and healing after my colon cancer diagnosis, transforming the act into a powerful recovery tool.

Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.

Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic lymphocytic leukemia.

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, myelofibrosis, and CLL.

After my cancer diagnosis, I built a strong medical team and support system that helped me heal; reaching out and accepting help made all the difference.